Syk kinase as a treatment target for therapy in autoimmune diseases.
Spleen tyrosine kinase (Syk) associates with a variety of immunoreceptors in myeloid and lymphoid cells. Syk initiates intracellular signaling once the receptor is engaged by its ligand. Blocking Syk may prove beneficial in interrupting the propagation of the abnormal immune response in both autoimmune and allergic diseases.
Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard Institutes of Medicine, HIM-238, 4 Blackfan Circle, Boston, MA 02115, USA. vkyttari@bidmc.harvard.edu
Vasileios C
VC
Kyttaris
George C
GC
Tsokos
D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008024:Ligands; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D017452:Receptors, IgG / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology; D000072377:Syk Kinase
D047908:Intracellular Signaling Peptides and Proteins; D008024:Ligands; D047428:Protein Kinase Inhibitors; D017452:Receptors, IgG; D011505:Protein-Tyrosine Kinases; C000606896:SYK protein, human; D000072377:Syk Kinase